| P50 | author | Shafaat Rabbani | Q77959450 |
| P2093 | author name string | David Goltzman | |
| | Anil Potti | |
| | Kanishka Sircar | |
| | Armen Aprikian | |
| | Gaoping Chen | |
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| | Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 |
| | RANK is essential for osteoclast and lymph node development | Q24598872 |
| | osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 |
| | Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation | Q24681552 |
| | RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis | Q28293009 |
| | Metastasis to bone: causes, consequences and therapeutic opportunities | Q29614310 |
| | Cancer statistics, 2005 | Q29617572 |
| | Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand | Q29619331 |
| | Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients | Q33904020 |
| | Receptor activator of NF-kappaB ligand (RANKL) is expressed in chondroblastoma: possible involvement in osteoclastic giant cell recruitment. | Q33919157 |
| | Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. | Q33979879 |
| | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma | Q35053943 |
| | Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score | Q35588857 |
| | Prostate cancer bone metastases promote both osteolytic and osteoblastic activity | Q35678564 |
| | Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis | Q35843398 |
| | Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. | Q38446601 |
| | Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin | Q39116155 |
| | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone | Q39946634 |
| | Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo--a role in tumour cell survival? | Q40374890 |
| | The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy. | Q40432075 |
| | Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteoprotegerin expression in osteoblasts | Q40440785 |
| | Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. | Q40772885 |
| | Osteoprotegerin and rank ligand expression in prostate cancer | Q42502915 |
| | A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases | Q44291815 |
| | Osteoprotegerin in prostate cancer bone metastasis. | Q51531894 |
| | MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. | Q53856850 |
| | Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. | Q54765911 |
| | In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells | Q57001253 |
| | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord | Q73766127 |
| | Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia | Q73904964 |
| | Expression and somatic mutation on androgen receptor gene in prostate cancer | Q78553788 |
| | Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma | Q80602463 |
| | The effect of osteoprotegerin administration on the intra-tibial growth of the osteoblastic LuCaP 23.1 prostate cancer xenograft | Q81323685 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 289-298 | |
| P577 | publication date | 2006-07-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation | |
| P478 | volume | 107 | |